According to Stratistics MRC, the Global Menopausal Hot Flashes Market is accounted for $17.27 billion in 2024 and is expected to reach $24.45 billion by 2030 growing at a CAGR of 7.2% during the forecast period. Menopausal hot flashes are sudden, intense feelings of heat that typically affect women in their late 40s to early 50s, marking the transition into menopause. These flashes can last from a few seconds to several minutes, accompanied by sweating, flushing of the face, and a rapid heartbeat. They are caused by hormonal fluctuations, particularly a decline in estrogen levels, which disrupt the body's temperature regulation.
According to an article published in the Journal of the North American Menopause Society in August 2021, it has been observed that the prevalence of vasomotor menopausal symptoms was high in the United States with 77%.
Market Dynamics:
Driver:
Global aging population
As women age, they are more likely to experience hot flashes, a common symptom of menopause, driving the demand for treatments and therapies to alleviate these symptoms. With a larger demographic entering menopausal age brackets, there's an increased market for pharmaceuticals, hormone therapies, and alternative remedies aimed at alleviating hot flashes and related discomfort. This demographic shift amplifies the focus on menopausal health, spurring innovation and investment in research and development within the menopausal hot flashes market.
Restraint:
Safety concerns
Safety concerns in the menopausal hot flashes market primarily revolve around the use of hormone replacement therapies due to potential risks such as increased likelihood of breast cancer, blood clots, and stroke. Additionally, there are concerns regarding the efficacy and safety of alternative treatments such as herbal supplements. These safety concerns hinder market growth by impacting patient confidence, leading to decreased adoption rates and reluctance among healthcare providers to prescribe certain treatments.
Opportunity:
Mounting modern lifestyles
Mounting modern lifestyles, characterized by stress, erratic sleep patterns, and unhealthy dietary habits, contribute to hormonal imbalances in women, exacerbating menopausal symptoms like hot flashes. Increased prevalence of sedentary lifestyles and environmental factors also play a role. Pharmaceutical companies respond with innovative treatments and therapies to address this growing consumer need. As women seek effective solutions to manage their symptoms and maintain their quality of life, the market for products targeting menopausal hot flashes expands rapidly.
Threat:
Rising availability of alternative therapies
The increasing availability of alternative therapies for menopausal hot flashes, such as herbal supplements, acupuncture, and lifestyle changes, poses a challenge to the growth of traditional pharmaceutical treatments. Additionally, the efficacy and safety of some alternative therapies may not be thoroughly researched or regulated, leading to uncertainties among patients and healthcare providers. This shift reduces demand for conventional medications, impacting market growth.
Covid-19 Impact
The covid-19 pandemic has impacted the menopausal hot flashes market by disrupting healthcare services, delaying diagnosis, and reducing patient visits. Supply chain disruptions have affected the availability of medications and treatments. Economic uncertainties have led to financial constraints among patients, affecting their ability to afford treatments. However, increased telemedicine adoption and virtual consultations have partially mitigated these challenges by providing alternative healthcare access options.
The hormonal treatment segment is expected to be the largest during the forecast period
The hormonal treatment segment is estimated to have a lucrative growth. Hormonal treatments for menopausal hot flashes often involve hormone replacement therapy (HRT), which includes estrogen alone or combined with progesterone. These treatments help regulate hormone levels, alleviating symptoms like hot flashes. HRT can be administered through pills, patches, gels, or creams. It's effective but may carry risks such as blood clots, stroke, or breast cancer, so it's usually recommended for the shortest duration necessary and under medical supervision.
The women on hormone therapy segment is expected to have the highest CAGR during the forecast period
The women on hormone therapy segment is anticipated to witness the highest CAGR growth during the forecast period. Menopausal hot flashes in women on hormone therapy (HT) can be effectively managed with estrogen or a combination of estrogen and progestin. HT helps reduce the frequency and severity of hot flashes by stabilizing hormone levels. However, it may have side effects and is not suitable for everyone. Women considering HT should discuss risks and benefits with their healthcare provider to determine the best course of action for their symptoms.
Region with largest share:
Asia Pacific is projected to hold the largest market share during the forecast period. Increasing awareness about menopausal health, coupled with a rising aging population, particularly in countries like Japan and South Korea, is driving market expansion. The adoption of Western lifestyles, including dietary changes and sedentary habits, is contributing to a higher prevalence of menopausal symptoms. Nevertheless, advancements in telemedicine and increasing healthcare infrastructure are gradually addressing these barriers, fostering market development.
Region with highest CAGR:
North America is projected to have the highest CAGR over the forecast period. The region's aging population, combined with a high level of awareness about menopausal symptoms and their management, drives demand for effective treatments. Technological advancements in pharmaceuticals offer innovative solutions, although safety concerns regarding hormone therapy persist. The market in North America remains significant, with a range of treatment options available to cater to the needs of women experiencing menopausal hot flashes.
Key players in the market
Some of the key players profiled in the Menopausal Hot Flashes Market include Pfizer Inc., Allergan PLC, Bayer AG, Novartis AG, GlaxoSmithKline PLC, Johnson & Johnson, Novo Nordisk A/S, Teva Pharmaceutical Industries Limited, Mylan N.V., Amgen Inc., Merck & Co Inc., Perrigo Company, Astellas Pharma Inc., TherapeuticsMD Inc., Hisamitsu Pharmaceutical Corporation and Endo International PLC.
Key Developments:
In May 2023, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause1. VEOZAH is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat VMS due to menopause.
Products Covered:
- Tablets
- Patches
- Creams & Gels
- Injections
- Other Products
Treatment Types Covered:
- Hormonal Treatment
- Non-Hormonal Treatment
- Over-the-Counter (OTC) Products
- Alternative Therapies
Severities Covered:
Applications Covered:
- Perimenopausal & Postmenopausal Women
- Breast Cancer Patients
- Women on Hormone Therapy
- Other Applications
End Users Covered:
- Hospitals
- Homecare
- Specialty Clinics
- Other End Users
Regions Covered:
- North America
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances